Publication date: Jul 11, 2023
As part of a multicenter study evaluating homologous and heterologous COVID-19 booster vaccines, we assessed the magnitude, breadth, and short-term durability of binding and pseudovirus-neutralizing antibody (PsVNA) responses following a single booster dose of NVX-CoV2373 in adults primed with either Ad26. COV2. S, mRNA-1273, or BNT162b2 vaccines. NVX-CoV2373 as a heterologous booster was immunogenic and associated with no safety concerns through Day 91. Fold-rises in PsVNA titers from baseline (Day 1) to Day 29 were highest for prototypic D614G variant and lowest for more recent Omicron sub-lineages BQ. 1.1 and XBB. 1. Peak humoral responses against all SARS-CoV-2 variants were lower in those primed with Ad26. COV2. S than with mRNA vaccines. Prior SARS CoV-2 infection was associated with substantially higher baseline PsVNA titers, which remained elevated relative to previously uninfected participants through Day 91. These data support the use of heterologous protein-based booster vaccines as an acceptable alternative to mRNA or adenoviral-based COVID-19 booster vaccines. This trial was conducted under ClinicalTrials. gov: NCT04889209.
Open Access PDF
| Concepts | Keywords |
|---|---|
| Clinicaltrials | Ad26 |
| Humoral | Booster |
| Nct04889209 | Cov |
| Vaccines | Cov2 |
| Cov2373 | |
| Covid | |
| Day | |
| Heterologous | |
| Mrna | |
| Nvx | |
| Primed | |
| Psvna | |
| Sars | |
| Vaccines | |
| Variants |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | VO | NVX-CoV2373 |
| disease | MESH | COVID-19 |
| disease | VO | dose |
| disease | VO | Ad26.COV2.S |
| disease | MESH | infection |
| drug | DRUGBANK | Angelica archangelica root |
| disease | VO | vaccination |
| disease | MESH | complications |
| disease | VO | immunization |
| disease | VO | vaccine |
| disease | MESH | emergency |
| disease | VO | population |
| disease | VO | USA |
| disease | MESH | Infectious Diseases |
| pathway | REACTOME | Infectious disease |
| disease | IDO | infectious disease |
| disease | MESH | AIDS |
| disease | MESH | Allergy |
| drug | DRUGBANK | Coenzyme M |
| disease | IDO | history |
| disease | VO | adverse event |
| disease | VO | injection |
| disease | MESH | lymphadenopathy |
| disease | IDO | blood |
| disease | MESH | stroke |
| disease | MESH | seizure |
| disease | VO | primary vaccination |
| disease | IDO | assay |
| disease | VO | age |
| disease | VO | vaccine dose |
| disease | VO | boost vaccination |